IndustryCompany release

Atea's BEM/RZR meets Phase 3 C-BEYOND endpoints in HCV; company secures up to $200M Hercules credit facility

🇺🇸 Atea Pharmaceuticals, Inc. (AVIR) · Mon 09 Nov 2026

Atea Pharmaceuticals reported Q3 2026 results on November 9, 2026. Its Phase 3 C-BEYOND trial showed bemnifosbuvir/ruzasvir was non-inferior to Epclusa in hepatitis C (SVR 93.91% vs 94.75%), with C-FORWARD data expected in early 2027 and an FDA NDA targeted for mid-2027. Atea also signed a credit facility with Hercules Capital for up to $200 million, drawing $65 million at closing, and continues Phase 1 development of AT-587 for chronic hepatitis E.

Company's press release (SEC filing): Atea Pharmaceuticals, Inc. ↗

Brief written by VigiEye from the company's press release filed with the SEC. Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →